Abstract
Recently we demonstrated that normal polyspecific immunoglobulin given intravenously (IVIG) and plasma samples from patients treated with IVIG neutralize the mitogenic and cytokine-inducing activities of group A streptococcal (GAS) superantigens. Here we investigated whether this neutralizing activity is mediated by antibodies to these superantigens. IVIG and plasma samples collected from a patient with GAS necrotizing fasciitis post-IVIG infusions markedly inhibited the mitogenic activity elicited by the streptococcal pyrogenic exotoxins SpeB and SpeC, as well as by GAS culture supernatant. Immunoblot analysis showed marked increases in the levels of antibodies to SpeC and proteins in the GAS culture supernatant in post-IVIG over those of pre-IVIG plasma samples. Removal of antisuperantigen antibodies in IVIG by adsorption to SpeC- and GAS culture supernatant-coupled Sepharose markedly reduced the neutralizing ability of IVIG against respective stimuli. The neutralizing activity was totally recovered in the eluted antibodies. By contrast, although pre- and post-IVIG plasma samples contained antibodies to SpeA, these antibodies did not block the activity of this superantigen. Nonspecific immunomodulatory activity of IVIG was ruled out because neither the IVIG nor the affinity-purified antibodies significantly inhibited the response to the polyclonal T-cell mitogen phytohemagglutinin A. These data provide direct evidence that the neutralizing activity in IVIG, and in patient plasma samples following IVIG treatment is mediated by antibodies to superantigens and indicate that the quality rather than the quantity of these antibodies may be more clinically relevant.
MeSH Terms
Adult
Antibodies, Bacterial/immunology
Humans
Immunoglobulin G/immunology
Immunoglobulins, Intravenous
Male
Streptococcus/immunology
Superantigens/immunology
Chemicals
Antibodies, Bacterial
Immunoglobulin G
Immunoglobulins, Intravenous
Superantigens
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Norrby-Teglund A
Research Service, Veterans Affairs Medical Center, Memphis, Tennessee 38104, USA.
Kaul R
Low D E
McGeer A
Andersson J
Andersson U
Kotb M
References (13)
13 references, click to expand
-
Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).
Infect Immun. 1994 Dec;62(12):5227-33
PMID: 7960098
-
Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project.
J Infect Dis. 1995 Jan;171(1):74-84
PMID: 7798684
-
Bacterial pyrogenic exotoxins as superantigens.
Clin Microbiol Rev. 1995 Jul;8(3):411-26
PMID: 7553574
-
Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
J Immunol. 1996 Apr 15;156(8):3057-64
PMID: 8609429
-
The staphylococcal enterotoxins and their relatives.
Science. 1990 May 11;248(4956):705-11
PMID: 2185544
-
Invasive group A streptococcus infections.
Clin Infect Dis. 1992 Jan;14(1):2-11
PMID: 1571429
-
Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease.
J Infect Dis. 1994 Sep;170(3):585-91
PMID: 8077715
-
Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment].
J Clin Invest. 1993 Feb;91(2):602-7
PMID: 8432865
-
Role of superantigens in human disease.
J Infect Dis. 1993 May;167(5):997-1002
PMID: 8486972
-
T cell activation and cytokine release in streptococcal toxic shock-like syndrome.
J Pediatr. 1993 May;122(5 Pt 1):727-9
PMID: 8496751
-
A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C.
J Clin Invest. 1993 Aug;92(2):710-9
PMID: 8349810
-
Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG.
Eur J Immunol. 1994 Apr;24(4):916-22
PMID: 8149962
-
Intravenous immunoglobulin therapy for toxic shock syndrome.
JAMA. 1992 Jun 24;267(24):3315-6
PMID: 1597914